Diabetic kidney disease therapies encompass a range of pharmacological interventions designed to slow renal impairment, reduce proteinuria and improve patient outcomes. Leading products include sodium-glucose cotransporter-2 (SGLT2) inhibitors, renin-angiotensin-aldosterone system (RAAS) blockers, endothelin receptor antagonists and novel biologics in clinical development. https://www.patreon.com/posts/diabetic-kidney-129984798?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=postshare_creator&utm_content=join_link